Publication | Closed Access

Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial

ObesityMetabolic SyndromeHepatologyNonalcoholic Fatty Liver DiseaseLiver PhysiologyObesity ManagementLiver DiseaseFatty Liver DiseasePublic HealthMedicineHigh BmiHealth Sciences